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IMPORTANCE Guidelines recommend against antibiotic use to treat asthma attacks. A study
with telithromycin reported benefit, but adverse reactions limit its use.
OBJECTIVE To determine whether azithromycin added to standard care for asthma attacks in
adults results in clinical benefit.
DESIGN, SETTING, AND PARTICIPANTS The Azithromycin Against Placebo in Exacerbations of
Asthma (AZALEA) randomized, double-blind, placebo-controlled clinical trial, a United
Kingdom–basedmulticenter study in adults requesting emergency care for acute asthma
exacerbations, ran from September 2011 to April 2014. Adults with a history of asthma for
more than 6months were recruited within 48 hours of presentation to medical care with an
acute deterioration in asthma control requiring a course of oral and/or systemic
corticosteroids.
INTERVENTIONS Azithromycin 500mg daily or matched placebo for 3 days.
MAIN OUTCOMES ANDMEASURES The primary outcomewas diary card symptom score 10
days after randomization, with a hypothesized treatment effect size of −0.3. Secondary
outcomes were diary card symptom score, quality-of-life questionnaires, and lung function
changes, all between exacerbation and day 10, and time to a 50% reduction in symptom
score.
RESULTS Of 4582 patients screened at 31 centers, 199 of a planned 380were randomized
within 48 hours of presentation. Themajor reason for nonrecruitment was receipt of
antibiotics (2044 [44.6%] screened patients). Median time from presentation to drug
administration was 22 hours (interquartile range, 14-28 hours). Exacerbation characteristics
were well balanced across treatment arms and centers. The primary outcome asthma
symptom scores were mean (SD), 4.14 (1.38) at exacerbation and 2.09 (1.71) at 10 days for the
azithromycin group and 4.18 (1.48) and 2.20 (1.51) for the placebo group, respectively. Using
multilevel modeling, there was no significant difference in symptom scores between
azithromycin and placebo at day 10 (difference, −0.166; 95% CI, −0.670 to 0.337), nor on any
day between exacerbation and day 10. No significant between-group differences were
observed in quality-of-life questionnaires or lung function between exacerbation and day 10,
or in time to 50% reduction in symptom score.
CONCLUSIONS AND RELEVANCE In this randomized population, azithromycin treatment
resulted in no statistically or clinically significant benefit. For each patient randomized, more
than 10 were excluded because they had already received antibiotics.
TRIAL REGISTRATION clinicaltrials.gov Identifier: NCT01444469
JAMA Intern Med. doi:10.1001/jamainternmed.2016.5664
Published online September 19, 2016.
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A sthmamorbidity,mortality, andmajorhealthcarecostsresult from acute attacks (exacerbations).1 Themajor-ity of patients with asthma report an exacerbation in
the past year, withmore than one-third of children andmore
than one-fourth of adults requiring consequent urgentmedi-
cal care.2
Respiratoryviral infections are a frequent causeof asthma
exacerbations in children3,4 and adults.5-7 Atypical bacterial
(MycoplasmapneumoniaeandChlamydophilapneumoniae) in-
fection and/or reactivation is also associated, with serologic
positivity rates of 40% to 60% in some studies,8-12 indicating
that viral and atypical bacterial infections may interact in in-
creasing asthma exacerbation risk.
Peoplewithasthmahave increased susceptibility to strep-
tococcal infections,13-15 increased carriage of bacterial patho-
gens identified by culture16 and molecular techniques,17 and
impaired interferon and type 1 T helper cell responses to bac-
terial polysaccharides.18,19 Viral infection impairs antibacte-
rial innate immune responses20 and increases bacterial ad-
herence to bronchial epithelium.21 Thus, bacterial infections
are more common and more severe in patients with asthma,
viruses increase susceptibility tobacterial infection, andacute
wheezing episodes in children younger than 3 years were as-
sociated with both bacterial and viral infection.22
Patientswith asthmaexacerbations treatedwith telithro-
mycin had greater reductions in asthma symptoms, improve-
ment in lung function, and faster recovery compared with
placebo.12However, toxic effects to the liver limit telithromy-
cin treatment to life-threatening infections, andguidelines rec-
ommend that antibiotics should not be administered rou-
tinely in patients with asthma exacerbations.23,24
The Azithromycin Against Placebo in Exacerbations of
Asthma (AZALEA) study investigated the effectiveness of
azithromycin treatmentwhenadded to standardcare for adult
patients with asthma exacerbations, closely following the
telithromycin study design, with the aim of providing confir-
mation or otherwise of those results.
Macrolide antibiotics might benefit asthma exacerba-
tions through antimicrobial activity and/or anti-inflamma-
toryproperties25; andazithromycin,butnot telithromycin,has
been shown to have antiviral properties,26 augmenting pro-
duction of interferons that are deficient in patients with
asthma.19,27AmechanisticandexploratoryaimofAZALEAwas
todeterminewhether treatmentbenefitedpatientswith these
infections.
Methods
Study Design
This United Kingdom–based multicenter, double-blind, pla-
cebo-controlled study randomizedeligiblepatients to azithro-
mycin500mgdaily orplacebo for3daysonday 1 (visit 1),with
posttherapyassessmentsatvisitsondays5 (visit2) and 10 (visit
3) and for serum sampling at 6weeks (visit 4) (see trial proto-
col in Supplement 2).
Themain inclusioncriteriawere thatparticipantsbeadults
aged 18 to 55 years with any smoking history, aged 56 to 65
years with a less than 20 pack-year smoking history, or older
than 65 years with a less than 5 pack-year smoking history,
with a documented history of asthma for more than 6
months, and recruitment within 48 hours of presentation to
medical care with an acute deterioration in asthma control
(increased wheeze, dyspnea, and/or cough) necessitating a
course of oral and/or systemic corticosteroids (based on
clinical judgement by attending physicians) and a peak
expiratory flow (PEF) or forced expiratory volume in 1 sec-
ond (FEV1) less than 80% predicted or patient’s best at pre-
sentation, at recruitment, or in the time elapsed between
presentation and recruitment.
The main exclusion criteria were use of oral and/or sys-
temic antibiotics within 28 days of enrollment, need for in-
tensive care, substantial lungdiseaseother thanasthma, long-
termuse ofmore than 20mgoral corticosteroid daily, known
QT-interval prolongation, history of bradyarrhythmias and/or
tachyarrhythmias or uncompensated heart failure, and pa-
tients taking drugs known to prolong the QT interval.
The primary outcomewas diary card summary symptom
score,withsymptoms includingwheezing,breathlessness, and
coughing assessed at 10 days after randomization (as in the
telithromycinstudy).12Secondaryoutcomes includedtheacute
AsthmaQuality of LifeQuestionnaire (AQLQ), theminiAQLQ,
FEV1, forced vital capacity (FVC), FEV1/FVC, forced mid-
expiratory flow (FEF25%-75%), forced expiratory flow at 50%
expiration (FEF50%), PEF, and time to 50%reduction in symp-
tom score. Primary and secondary outcomes were assessed
over the time course of the exacerbation to 10 days, and sub-
group analyses were planned in relation to initial standard
and/or atypical bacteriologic and virologic status.
Spontaneous or induced sputum samples were obtained
where possible at exacerbation and sent for quantitative bac-
teria culture.Anasalmucus sample andnasal and throat swab
samples were obtained where possible at exacerbation, and
these and spontaneousor induced sputumsampleswere ana-
lyzedbymeansofviral andatypicalbacterialpolymerasechain
reactions (PCRs) and acute and convalescent serum samples
were sent for atypical bacterial serologic analysis.
The trial received approval from the National Research
Ethics Committee, Bloomsbury, London, England, and all pa-
tients gavewritten informedconsent. Additionalmethods are
available in the eMethods in Supplement 1.
Key Points
Question Does addition of azithromycin to standard care improve
outcomes in adults requesting acute medical care for asthma
attacks?
Findings This randomized clinical trial found no statistically or
clinically significant benefit in symptoms, lung function, or speed
of recovery. For every 1 patient randomized, more than 10 had to
be excluded because they had already received antibiotics.
Meaning Widespread use of antibiotics despite guideline
recommendations limited interpretation of the results of this
study.
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Statistical Analyses
The sample size calculations hypothesized a treatmentmean
(SD) effect size of −0.3 (0.783) based on the primary outcome
of the telithromycin study12 and used a significance level of
1%with80%power, assumingadropout rateof 15%.12Wepro-
posedto recruit 190patients toeacharm.Torunthe trialwithin
theproject funding 1-year timeline,weplanned 10centers,each
recruiting roughly 38 patients.
All patients who returned at least 1 diary card and re-
ceivedstudydrugwere included inthe intention-to-treatanaly-
ses. Because the timing of greatest magnitude of any treat-
ment effect was not known,multilevelmodelingwas used to
calculate the estimateddifferences in primary and secondary
outcomes between treatment groups for each day from ran-
domization to day 10. A Cox model was used to calculate the
hazard ratio for time to 50%reduction in symptom score. De-
tailsof thestatisticalmodel,model selectionprocess, andtreat-
ment ofmissingdata are in the eMethods in Supplement 1. All
analyses were performed using Stata 13. A statistical analysis
planwas prepared by the trial statistician prior to unblinding.
Results
Recruitment Details and Clinical Characteristics
Recruitment from 31 sites (30 secondary care hospitals, 1 pri-
mary care center) lasted 2.5 years, from October 12, 2011, to
April 30, 2014. The recruitment period was longer than
planned because of recruitment difficulties arising from the
large numbers of patients excluded. A total of 4582 patients
were screened, of whom 390 patients met eligibility criteria.
A total of 199 were randomized, 97 to active treatment and
102 to placebo (Figure 1). The major reason for nonrecruit-
ment was already receiving antibiotics (2044 [44.6%]
screened patients).
Clinical characteristics of randomized patients are sum-
marized inTable 1. Studyparticipants’mean (SD) agewas 39.9
(14.82) years (median [interquartile range] age, 38.4 [26.7-
49.5] years), with 69.8% female. Underlying asthma severity,
smoking status, exacerbation severity, andmedian time from
presentation to trial drug administration are presented in
Table 1. Pulmonary function at baseline (exacerbation, visit 1)
is presented in Table 2 and includes mean (SD) PEF, 69.4%
(22.7%) of predicted; FEV1, 64.8% (21.4%) of predicted; and
FEV1/FVC, 69.2% (13.5%). Baseline characteristics were well
balanced across treatment arms and centers.
Of the 199 patients randomized, all attended visit 1 (ran-
domization), 21 (10.6%)missed visit 2, 28 (14.1%)missed visit
3, and 39 (19.6%)missed visit 4; 159 (80%) patients attended
all follow-up visits. Missing visits and/or data were balanced
between the treatment arms. Day 1was defined as the day of
administration of study drug.
Primary Outcome Analysis
Mean (SD) asthma symptomscores (from0 = no symptoms to
6 = severe symptoms) were 4.14 (1.38) at baseline (exacerba-
tion) and 2.09 (1.71) at day 10 for the azithromycin group and
4.18 (1.48) and2.20 (1.51), respectively, forplacebo.Usingmul-
tilevel modeling, there was no statistically significant differ-
ence in symptom scores between groups at day 10 (differ-
ence, −0.166; 95%CI, −0.670 to 0.337) (Figure 2 and eTable 3
in Supplement 1).
Secondary Outcome Analyses
Multilevel modeling revealed no significant between-group
differences in symptom scores on any day between baseline
and day 10 (Figure 2 and eTable 3 in Supplement 1). Signifi-
cant between-group differences were seen in neither the
acute AQLQ, the mini AQLQ (Figure 3A and B and eTables
7-10 in Supplement 1), nor in any measure of lung function
(eTables 11 and 12 in Supplement 1) on any day from baseline
to day 10, and there was no difference in time to 50% reduc-
tion in symptom score (hazard ratio, 1.03; 95% CI, 0.71-1.49)
(Figure 3C).
Pathogen Detection Results
One hundred five (52.8%) patients provided sputum samples
forbacterial culture, 191 (96.0%)nasal and throat swabsand/or
nasalmucus samples for virus andatypical bacterial PCR, and
158 (79.4%)acute (IgM) and acute and convalescent (IgG, IgA)
serumsamples for atypical bacterial serologic analysis. A bac-
terial and/or atypical bacterial test positive result occurred in
21 (10.6%)patients (9 [9.3%]active, 12 [11.8%]placebo). Nasal
and/or throat swab and/or mucus and/or sputum virus PCRs
had positive results in 36 (18.1%) patients (16 [16.5%] active,
20 [19.6%] placebo).
Figure 1. Consolidated Standards of Reporting Trials Diagram
of the Azithromycin for Acute Exacerbations of Asthma (AZALEA) Trial
4582 Patients assessed for eligibility
97 Randomized to receive
azithromycin
97 Received azithromycin as
randomized
102 Randomized to receive placebo
102 Received placebo as
randomized
87 Symptom diary scores analyzed
96 Acute and Mini AQLQ scores
analyzed
97 Pulmonary functions analyzed
89 Symptom diary scores analyzed
100 Acute and Mini AQLQ scores
analyzed
101 Pulmonary functions analyzed
4383 Excluded
2044 Antibiotic treatment
660 Other
417 Underlying health condition
315 Discharged
259 Age
220 >48 Hours after presentation
191 Declined to participate
130 Unknown reason
110 No requirement for steroid
treatment
30 Not English speaking
7 No asthma exacerbation
199 Randomized
AQLQ indicates Asthma Quality of Life Questionnaire.
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Subgroup Analyses
There were no differences in the primary outcome asthma
symptom score between treatment groups in patients with
positivesputumbacterial culture results, atypicalbacterialPCR
and/or serologic analysis results, or virus PCR test results (in-
cluding anybacteria and/or virus positive test result) (eTables
13-15andeFigures6-8 inSupplement 1), althoughpatientnum-
bers for these analyses were low.
Safety
Adverse events were infrequent (eTables 16-22 in Supplement
1), with more gastrointestinal adverse events in the azithro-
mycin group compared with placebo (35 vs 24 events, respec-
tively) (eTable 16 in Supplement 1). There was an increased
frequency of cardiac adverse events (4 vs 2, respectively) in
the azithromycin group compared with placebo and a
reduced frequency of respiratory, thoracic, and mediastinal
Table 1. Baseline Characteristics of Patients by Treatment Group
Characteristic
Azithromycin
(n = 97)
Placebo
(n = 102)
Age, median (IQR), y 39.1 (28.9-49.5) 36.2 (25.4-49.3)
Sex, No. (%)
Male 33 (34) 27 (26)
Female 64 (66) 75 (74)
Asthma severity (n = 198),
No. (%)28
Step 1: mild intermittent
asthma
7 (7) 13 (13)
Step 2: regular preventer
therapy
30 (31) 26 (26)
Step 3: initial add-on
therapy
31 (32) 27 (27)
Step 4: persistent poor
control
22 (23) 22 (22)
Step 5: continuous/frequent
oral steroids
7 (7) 13 (13)
Smoking status, No. (%)
Never 60 (62) 61 (60)
Former 26 (27) 19 (19)
Current 11 (11) 21 (21)
Smoking pack-years for
current or former smokers
(n = 75), median (IQR) [range]
5 (1-12) [0-20] 5 (2-12) [0-22]
Asthma exacerbation
(n = 198), No. (%)
Mild exacerbation 5 (5) 3 (3)
Moderate exacerbation 26 (27) 35 (35)
Acute severe asthma 61 (63) 56 (55)
Life-threatening asthma 4 (4) 7 (7)
Near-fatal asthma 1 (1) 0
Time from presentation to
receipt of study drug
(n = 192), median (IQR), h
21 (12-29) 22 (14-28)
Abbreviation: IQR, interquartile range.
Figure 2. Primary Outcome SymptomDiary Scores FromRandomization
to Day 10
6
5
4
3
2
1
0
M
ea
n 
Di
ar
y 
Sc
or
e
Day
0 1 2 3 4 5 6 7 8 9 10
Active
Placebo
Error bars indicate standard error.
Table 2. Baseline (Exacerbation) Pulmonary Function by Treatment Arm
Pulmonary Function
Patients,
No. Mean (SD)
Percentile
25th 50th 75th
Azithromycin
FEV1, L 95 1.9 (0.7) 1.4 1.8 2.5
FEV1% predicted, % 93 63.2 (21.8) 48 63 79
FVC, L 96 2.8 (1.0) 2.0 2.7 3.5
FEV1/FVC ratio 94 69.7 (13.3) 62.0 70.0 79.0
FEF25%-75%, L/s 80 1.6 (0.9) 0.9 1.4 2.1
FEF50%, L/s 76 1.9 (1.1) 1.1 1.7 2.6
PEF, L/min 93 290 (104) 215 283 348
PEF % predicted, % 92 65.7 (23.4) 47.0 67.0 79.0
Placebo
FEV1, L 96 2.1 (0.8) 1.5 2.0 2.6
FEV1% predicted, % 96 66.3 (21.0) 52.5 64.0 84.0
FVC, L 96 3.1 (1.0) 2.4 3.0 3.6
FEV1/FVC ratio 96 68.8 (13.7) 58.0 69.0 79.5
FEF25%-75%, L/s 87 1.7 (1.1) 0.9 1.4 2.4
FEF50%, L/s 84 2.0 (1.3) 1.1 1.7 2.8
PEF, L/min 96 323 (98) 248 341 390
PEF % predicted, % 95 73.0 (21.5) 56.0 75.0 90.0
Abbreviations: FEF25%-75%, forced
mid-expiratory flow; FEF50%, forced
expiratory flow at 50% expiration;
FEV1, forced expiratory volume in 1
second; FEV1/FVC, ratio of forced
expiratory volume in 1 second to
forced vital capacity; FVC, forced vital
capacity; PEF, peak expiratory flow.
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(63 of 64 respiratory) adverse events (27 vs 37, respectively)
(eTables 16 and 20 in Supplement 1), suggesting that antibi-
otic therapy possibly reduced respiratory adverse events in
this population.
Discussion
In thepatientswithasthmaexacerbations randomized to treat-
ment or placebo in this study, the addition of azithromycin to
standardmedicalcareresulted innostatisticallyorclinicallysig-
nificant therapeutic benefit. The findings were consistently
negative across3different symptomandquality-of-life scores,
including 1 previously reporting statistically and clinically sig-
nificant benefit with telithromycin treatment.12 The findings
were also negative for allmeasures of lung function, including
FEV1,whichwassignificantly improved in thepreviousstudy,12
and for time to a 50% reduction in asthma symptoms, which
was significantly improved in the previous study.12
Recruitmentprovedchallenging; initially therewere 10cen-
ters, each aiming to recruit 38 participants over 1 winter sea-
son, to recruit the planned 380 patients. Our power calcula-
tion deliberately mandated large patient numbers to provide
statistically robust data to settle the important clinical ques-
tion regarding antibiotic efficacy in this setting (for compari-
son,thetelithromycinstudyrandomized270patients).12Wealso
desired larger patient numbers to enhance subgroup analyses
aimedatpotentially importantmechanisticquestions.Once re-
cruitment obstacles became clear with such widespread anti-
biotic use, a total of 31 centerswere enrolled, inclusion criteria
were relaxed to change eligibility criteria from less than 24 to
less than 48 hours from time of presentation, to include older
participants with low smoking histories, and recruitment was
extended to 2 years and 7months. However, despite all these
efforts, only 199participantswere recruitedbymedication ex-
piry and funding end dates and the study was terminated de-
spite not reaching its recruitment target. The studywas there-
fore underpowered and a difference of 0.3 in mean symptom
score between treatment arms at 10 days cannot be excluded.
The different outcomes of the present and previous
studies,12whichused closely related therapies in similar study
designs, require interpretation and/or explanation. The antibi-
otics studiedaredifferent, albeit related.Bothdrugswereused
at their standardrecommendeddosesanddurationsof therapy.
Theshorterdurationof treatmentwithazithromycin (3daysvs
10 days with telithromycin) is unlikely to explain the differ-
ence in outcome because azithromycin has a long tissue half-
life and is likely to have remained at therapeutic doses in the
lungforapproximately 10days.29Azithromycinbutnot telithro-
mycin has antiviral activity,26 so this is an unlikely explana-
tion. In terms of antibacterial activity against relevant respira-
tory bacteria, telithromycin is reportedly more active than
azithromycin against Streptococcus pneumoniae but has simi-
lar activity against bothMoraxella catarrhalis and Haemophi-
lus influenzae.30-32 Because the present study only detected 3
S pneumoniae, 1M catarrhalis, and no H influenzae infections
in theactive treatmentarm,differences inactivityagainst these
organisms seemunlikely to explain the differing outcomes. In
terms of anti-inflammatory activities, both drugs reportedly
have similar activities when compared.25
A remarkable finding of this study was the number of pa-
tients (2044) excludedbecause theywerealready receivingan-
tibiotic therapy for their asthma exacerbation despite treat-
ment guidelines recommending that such therapy not be
routinely given.23,24 For each patient randomized, more than
10 were excluded for this reason. This important finding has
obvious and worrying implications regarding antibiotic
stewardship33; in addition, such high antibiotic use rates may
also have directly influenced the study outcome because it is
Figure 3. Secondary Outcome Acute andMini AsthmaQuality of Life
Questionnaire (AQLQ) Scores FromRandomization to Day 10 and Time
to 50%Reduction in SymptomDiary Score
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A and B, Acute andMini AQLQmean scores by visits for each treatment arm.
Error bars indicate standard error. C, Kaplan-Meier curves of time to a 50%
reduction in symptomdiary score for each treatment arm (truncated at 10 days).
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possible that patients who might potentially have benefitted
fromantibiotic therapy for their asthmaexacerbation (through
having sputum production, sputum purulence, fever) were
excludedfromthestudythroughalreadyhavingreceivedthem.
The population remaining to be randomized could theoreti-
cally have been selected against for antibiotic responsiveness,
through having no clinical indication that antibiotic therapy
might be of benefit. This is possible because patients being
screened had often been seen by their primary care practi-
tioner, byemergencydepartmentmedical staff, andbyamem-
ber of the on-call respiratory and/ormedical team, so inmany
instances 3 independent physicians and/or teams had as-
sessed them, including their suitability for antibiotic therapy.
It is likely therefore that those not prescribed antibiotics were
negatively selected against, for suitability for antibiotics. This
interpretation is supported by the low bacterial and/or atypi-
cal bacterial positivity rate found in this study: only 9.3% of
azithromycin-treated participants.
It is also possible that the population randomizedwere in
otherwaysnot representativeof the largerpopulationscreened
because more than 2000 other patients were excluded from
the study for other reasons (Figure 1). The telithromycin study
didnot report numbers of patients screened,12 so it is not pos-
sible to determine towhat extent these caveatsmay alsohave
applied to that study.
A further difference is that all patients randomized to this
studywere required tobeprescribedoral and/or systemic cor-
ticosteroid treatment,whereas in the telithromycin studyonly
34.1%ofpatients randomized toactive treatment requiredcor-
ticosteroid therapy.12 Requirement for corticosteroid treat-
ment in this studywasdesignedtoreducethenumberofmilder
exacerbations studied.However, if our study included largely
non–bacterially infected participants, this could have re-
sulted in us studying possible anti-inflammatory effects of
azithromycin, in the face of the powerful anti-inflammatory
effects of corticosteroids, with predictably negative results.
Theclinical characteristicsof thepatients inourstudycom-
pared with those in the telithromycin study were similar in
terms of mean age (39.9 years in our study vs 39.5 in the
telithromycin study), sex (30.2%male vs 32%), smoking sta-
tus (mean of 3.44 vs 2.15 pack-years), exacerbation symptom
score severity (4.16 vs 2.9), and lung function at exacerbation
(PEF, 69.4% vs 55.2% of predicted; FEV1, 64.8% vs 67.2% of
predicted; FEV1/FVC, 69.2%vs 72%).12Differences in clinical
characteristics donot seema likely explanation for the differ-
ence in outcome of the 2 studies.
Thestudiesdifferedstrikingly inoneregard:61%oftelithro-
mycin-treated but only 5.2%of azithromycin-treated patients
hadapositivetest result forcurrentatypicalbacterial infection.12
Both studies used similar sampling and detection methods,
although the laboratoriesperforming theanalysesdiffered (GR
Micro London, England, for telithromycin; S.L.J.’s laboratory
for this study). Detection rates by PCRwere low in both stud-
ies (3positive in the telithromycin study and0positive in this
study). In contrast, serological positive results differedmark-
edly: the telithromycin study positive results were almost all
C pneumoniae IgMpositives, while in our study only 1 sample
was IgMpositive for thisorganism.Both studiesused the same
assay (MedacCpneumoniae IgMsandwichenzyme-linked im-
munosorbent assay, Medac) so the discrepancy between the
results of this assay is difficult to explain. This major differ-
ence in frequency of C pneumoniae IgM positivity may have
contributed to thedifference in clinical outcomesbetween the
2 studies.
Sputumculture for standardbacteriawasnotperformed in
the telithromycinstudy.12 In thepresent study, 105 (52.8%)par-
ticipants provided sputum samples for bacterial culture and
positivity was observed in 6.0% (4.1% active, 7.8% placebo).
These results, togetherwith the negative outcomes in relation
to therapy, suggest that the role of standard bacterial infection
in the population studied was unlikely to be important.
Interpretationof theoutcomeof this studymustbeconsid-
ered in the light of prior knowledge that noninfectious agents
canalsotriggerexacerbations,andofotherrandomizedplacebo-
controlled studies investigating theeffects of similar therapies
in acute wheezing episodes. In addition to the telithromycin
study reportingpositive outcomes in asthmaexacerbations in
adults,12azithromycintreatmentduringbronchiolitis in infancy
was reported to reduce nasal lavage interleukin 8 levels, the
occurrence of postbronchioliticwheezing,34 and theduration
of acute episodes of asthma-like symptoms in 1- to 3-year-old
children.35Furthermore, in 1- to 6-year-old childrenwith his-
tories of recurrent severe lower respiratory tract infections
(LRTIs), azithromycin treatment early during an apparent re-
spiratorytract infectionreducedthe likelihoodofsevereLRTI.36
Finally, low-doseazithromycinprophylaxis for6months inpar-
ticipantswithexacerbation-pronesevereasthmadidnotreduce
the primary outcome (rate of severe exacerbations and LRTIs
necessitating treatment with antibiotics); however, in a pre-
defined subgroup analysis according to inflammatory pheno-
type, azithromycin treatment benefitted participants with
noneosinophilic severe asthma.37 We therefore carried out a
similarposthocanalysisbut foundnoevidenceofbenefit in this
subgroup (eResults in Supplement 1). Thus, further study of
azithromycin treatment in acute exacerbations of asthma in
adults andchildren in settingsof lowratesof antibioticuseand
stratifyingonbloodand/or sputumcell counts seems justified.
Conclusions
In the patients randomized to treatment or placebo in this
study, addition of azithromycin to standard medical care re-
sulted innostatistically significantor clinically importantben-
efit.However, for eachpatient randomized,more than 10were
excluded because they had already received antibiotics.
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